A Study of TY-1091 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic
activity of TY-1091 administered orally in participants with medullary thyroid cancer (MTC),
RET-altered NSCLC and other RET-altered solid tumors.